Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: Effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants

Pediatrics

Volumn 123, Issue 3, 2009, Pages

  Wilson Costello, Deanne ^a,j   Walsh, Michele C ^a   Langer, John C ^b   Guillet, Ronnie ^c   Laptook, Abbot R ^d   Stoll, Barbara J ^e   Shankaran, Seetha ^f   Finer, Neil N ^g   Van Meurs, Krisa P ^h   Engle, William A ⁱ   Das, Abhik ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

Extremely low birth weight infants; Neurodevelopmental impairment; Postnatal corticosteroids

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; ANTIINFLAMMATORY AGENT;

ARTICLE; BRAIN DISEASE; CEREBRAL PALSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DOSE RESPONSE; EXTREMELY LOW BIRTH WEIGHT; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; NERVE CELL DIFFERENTIATION; NEWBORN MORBIDITY; NEWBORN MORTALITY; PERINATAL PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSORY DYSFUNCTION; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; FOLLOW UP; GESTATIONAL AGE; MORTALITY; MULTICENTER STUDY; NEWBORN; SURVIVAL RATE;

ANTI-INFLAMMATORY AGENTS; BRONCHOPULMONARY DYSPLASIA; CEREBRAL PALSY; COHORT STUDIES; DEVELOPMENTAL DISABILITIES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; PROSPECTIVE STUDIES; SENSATION DISORDERS; SURVIVAL RATE;

EID: 63149147388     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-1928     Document Type: Article

References (52)

1. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants [Cochrane review]. In: The Cochrane Library. Issue 1. Chichester, United Kingdom: John Wiley and Sons; 2004
2. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants [Cochrane review]. In: The Cochrane Library. Issue 1. Chichester, United Kingdom: John Wiley and Sons; 2004
3. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants [Cochrane review] In: The Cochrane Library. Issue 1. Chichester, United Kingdom: John Wiley and Sons; 2004
4. Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants: Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001; 344(2):95-101
5. Stoll BJ, Temprosa M, Tyson J, et al. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics. 1999;104(5). Available at: www.pediatrics.org/cgi/content/full/104/5/e63
6. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001;1:1
7. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83(3):F177-F181
8. Murphy BP, Indur TE, Huppi PS, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001;107(2): 217-221
9. Haroon Parupia P, Dhanireddy R. Association of postnatal dexamethasone use and fungal sepsis in the development of severe retinopathy of prematurity and progression to laser therapy in extremely low-birth-weight infants. J Perinatol. 2001;21(4):242-247
10. Short EJ, Klein NK, Lewis BA, et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics. 2003;112(5). Available at: www.pediatrics.org/cgi/content/ full/112/5/e359
11. LeFlore JL, Salhab WA, Broyles RS, Engle WD. Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates. Pediatrics. 2002; 110(2 pt 1):275-279
12. American Academy of Pediatrics, Committee on Fetus and Newborn and Canadian Paediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109(2):330-338
13. Kaempf JW, Campbell B, Sklar RS, et al. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics. 2003;111(4 pt 2). Available at: www.pediatrics.org/cgi/content/full/111/4/e534
14. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Low dose dexamethasone facilitates extubation among critically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117(1):75-83
15. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115(3):655-661
16. Walsh MC, Laptook A, Kazzi N, et al. A cluster randomized trial of benchmarking and multi-modal quality improvement to improve rates of survival free of bronchopulmonary dysplasia for infants with birth weights of less than 1250 grams. Pediatrics. 2007;119(5):876-890
17. Haynes RC, Murad F. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of adrenocortical steroid biosynthesis. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The Pharmacological Basis of Therapeutics. New York, NY: Macmillan Publishing Company; 1985:1475
18. Kramer MS, Platt RW, Wen SW, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001;108(2). Available at: www.pediatrics.org/cgi/content/full/108/2/e35
19. Richardson DK, Phibbs CS, Gray JE, et al. Birth weight and illness severity: independent predictors of neonatal mortality. Pediatrics. 1993;91(5):969-975
20. Romagnoli C, Zecca E, Tortorolo L, Vento G, Tortorolo G. A scoring system to predict the evolution of respiratory distress syndrome into chronic lung disease in preterm infants. Intensive Care Med. 1998;24(5):476-480
21. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol. 2003;23(6):451-456
22. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhages: a study of infants with birth weights less than 1500 grams. J Pediatr. 1978;92(4):529-534
23. Quinn GE, Schaffer DB, Johnson L. A revised classification of retinopathy of prematurity. Am J Ophthalmol. 1982;94(6):744-749
24. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991-999
25. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis; therapeutic decisions based on clinical staging. Ann Surg. 1978;187(1):1-7
26. Amiel-Tison C, Stewart AL. Follow-up studies in the first five years of life: a pervasive assessment of neurologic function. Arch Dis Child. 1989;64(4):496-502
27. Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corp; 1993
28. Bax M. Terminology and classification of cerebral palsy. Dev Med Child Neurol. 1964;6:295-297
29. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics. 2006;118(5). Available at: www.pediatrics.org/cgi/ content/full/118/5/e1328
30. Shinwell ES, Lerner-Geva L, Lusky A, Reichman B. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2007;92(1):F30-33
31. Kumar P. Effect of decreased use of postnatal corticosteroids on morbidity in extremely low birthweight infants. Am J Perinatol. 2005;22(2):77-81
32. Truffert P, Empana JP, Breart G, et al. Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe: the EURAIL survey. Acta Paediatr. 2003;92(8):948-951
33. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42 day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcomes of study participants at 1-year adjusted age. Pediatrics. 1999;104(1 pt 1):15-21
34. Gross SJ, Anbar RD, Mettelmann BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics. 2005;115(3):681-687
35. Kobaly K, Schluchter M, Friedman H, et al. Outcomes of extremely low birth weight (<1 kg) and extremely low gestational age (<28 week) infants with bronchopulmonary dysplasia: effects of practice change in 2000-2003. Pediatrics. 2008;121(1):73-81
36. Slotkin TA, Keider ML, Tate CA, Seidler FJ. Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems. Neuropsychopharmacology. 2006;31(5):904-911
37. McGowan JE, Sysyn G, Peterson KH, et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci. 2000;20(19):7424-7429
38. Kreider ML, Tate CA, Cousins MM, et al. Lasting effects of developmental dexamethasone treatment on neural cell number and size, synaptic activity, and cell signaling: critical periods of vulnerability, dose-effect relationships, regional targets and sex selectivity. Neuropsychopharmacology. 2006;31(1):12-35
39. Powell K, Kerkering KW, Barker G, Rozycki HJ. Dexamethasone dosing, mechanical ventilation and the risk of cerebral palsy. J Maternal Fetal Neonatal Med. 2006;19(1):43-48
40. Arias-Camison JM, Lau J, Cole CH, Frantz ID. Meta-analysis of dexamethasone therapy started in the first 15 days of life for the prevention of chronic lung disease in premature infants. Pediatr Pulmonol. 1999;28(3):167-174
41. Shah V, Ohlsson A. Postnatal dexamethasone in the prevention of chronic lung disease. In: David TJ, ed. Recent Advances in Pediatrics 19. London, England: Churchill Livingstone; 2001:77-96
42. Yeh TF, Lin YL, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350(13):1304-1313
43. Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics. 2001;108(3):741-748
44. Halliday HL. Postnatal dexamethasone: what is the real cost-benefit ratio? Acta Paediatr. 2003;92(8):888-889
45. Hofkosh D, Brozanski BS, Edwards MD, et al. One year outcome of infants treated with pulse dexamethasone for prevention of BPD [abstract]. Pediatr Res. 1995;37:259
46. McEwen BS. The brain is an important target of adrenal steroid actions: a comparison of synthetic and natural steroids. Ann NY Acad Sci. 1997;823:201-213
47. De Kloet RE, Vreugdenhill E, Oitzl MS, Joel M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19(3):269-301
48. Ferguson SA, Paule MG, Holson RR. Neonatal dexamethasone on day 7 in rats causes behavioral alterations reflective of hippocampal, but not cerebellar deficits. Neurotoxicol. Teratol. 2001;23(1):57-69
49. Hassan AHS, von Rosenstiel P, Patchev VK, Holsboer F, Almeida OFX. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol. 1996;140(1):43-52
50. Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005;116(1):1-7
51. Van der Heide-Jalving M, Kamphuis PJGH, van der Laan MJ, et al. Short and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr. 2003;92(7):827-835
52. Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics. 2007;120(1):40-48